[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN: Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke; 2002 Jun;33(6):1685-91
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone.
  • BACKGROUND AND PURPOSE: In vivo and in vitro rat models of hormone therapy were used to test the following hypotheses:.
  • (2) increased protein correlates with higher NOS activity; and (3) effects of estrogen on eNOS are altered by concurrent treatment with either medroxyprogesterone acetate (MPA) or progesterone.
  • Levels of eNOS were measured by Western blot, and NOS activity was measured by [14C]arginine-[14C]citrulline conversion.
  • RESULTS: Chronic hormone treatment in vivo resulted in plasma levels of 17beta-estradiol, progesterone, and MPA in the range of values found in humans.
  • Estrogen treatment resulted in higher levels of cerebrovascular NOS activity that paralleled increases in eNOS protein.
  • In vitro estrogen treatment for 18 hours also resulted in a concentration-dependent increase in eNOS protein (EC50 approximately 300 pmol/L) that was completely prevented by estrogen receptor antagonists tamoxifen or ICI 182 780.
  • CONCLUSIONS: Estrogen receptor activation in cerebrovascular tissue results in increased eNOS activity and protein levels.
  • [MeSH-minor] Animals. Body Weight / drug effects. Brain / blood supply. Dose-Response Relationship, Drug. Drug Implants. Enzyme Activation / drug effects. Estrogen Replacement Therapy. Female. In Vitro Techniques. Models, Animal. Nitric Oxide Synthase Type III. Organ Size / drug effects. Ovariectomy. Rats. Rats, Inbred F344. Tamoxifen / pharmacology. Uterus / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053012.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL50775
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Estrogens; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 22X328QOC4 / fulvestrant; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos3 protein, rat
  •  go-up   go-down


2. Chen J, Hui E, Ip T, Thompson LU: Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res; 2004 Nov 15;10(22):7703-11
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
  • PURPOSE: This study determined the effect of 10% dietary flaxseed (FS) and tamoxifen (TAM), alone and in combination, on the growth of estrogen-dependent human breast cancer (MCF-7) in athymic mice with or without 17beta-estradiol (E2) supplementation.
  • When tumor reached approximately 40 mm2, the E2 implant was removed, and mice were randomized to the following groups and maintained at either low (E2 pellet removed) or high E2 level (new E2 pellet implanted) for 6 weeks: (a) positive control with new E2 pellet, fed BD, (b) negative control with no E2 implant, fed BD, (c) TAM group with TAM pellet (5 mg) implant, fed BD, (d) FS group fed 10% FS, (e) FS+TAM group with TAM implant, fed 10% FS.
  • Tumor growth was monitored weekly.
  • RESULTS: At low E2 level, FS regressed the pretreatment tumor size by 74%.
  • TAM regressed tumor initially but later induced an increase so that the tumor size was finally similar to the pretreatment size.
  • A tumor regression >53% was induced by FS+TAM than by TAM alone.
  • At high E2 level, FS, TAM, and FS+TAM inhibited the tumor growth by 22, 41, and 50%, respectively, compared with the positive control.
  • Decreased tumor size was attributable to reduced tumor cell proliferation and increased apoptosis.
  • CONCLUSIONS: FS inhibited the growth of human estrogen-dependent breast cancer and strengthened the tumor-inhibitory effect of TAM at both low and high E2 levels.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Flax. Tamoxifen / pharmacology
  • [MeSH-minor] Animal Feed. Animals. Apoptosis. Body Weight. Cell Line, Tumor. Cell Proliferation. Diet. Estradiol / therapeutic use. Estrogens / metabolism. Female. Humans. Ki-67 Antigen / biosynthesis. Mice. Mice, Inbred BALB C. Mice, Nude. Models, Chemical. Neoplasms / metabolism. Organ Size. Seeds. Time Factors. Uterus / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570004.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA100639-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Ki-67 Antigen; 094ZI81Y45 / Tamoxifen; 4TI98Z838E / Estradiol
  •  go-up   go-down


3. Xie F, Wu CF, Zhang Y, Yao XS, Cheung PY, Chan AS, Wong MS: Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. Biol Pharm Bull; 2005 Oct;28(10):1879-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herbal Sambucus williamsii HANCE (SWH) is a folk medicine with a long history of safe use for treatment of bone fractures and joint diseases in China.
  • The present study was designed to investigate if SWH extract could be used for treatment of postmenopausal osteoporosis.
  • SWH extracts (30 or 60 mg/100 g body weight/d) were orally administrated to four-months-old ovariectomized (OVX) rats for 3 months.
  • SWH extracts did not alter weight gain and uterus weight in OVX rats.
  • SWH extracts significantly increased serum Ca levels (p<0.05, vs.
  • OVX control group) as well as decreased urinary Ca excretion (p<0.01, vs. OVX control group) in OVX rats.
  • The upregulation of serum alkaline phosphatase, serum osteocalcin as well as urinary deoxypyridinoline levels by OVX was suppressed by treatment with SWH extracts in rats (p<0.05, vs. OVX control group).
  • OVX control group) and increased tibial bone mineral density at 60 mg/100 g body weight/d (p<0.05, vs. OVX control group) in OVX rats.
  • Taken together, SWH treatment can effectively suppress the OVX-induced increase in bone turnover and its effects might be mediated by a decrease in osteoclastogenesis.
  • [MeSH-major] Bone and Bones / drug effects. Organ Size / drug effects. Osteoporosis / drug therapy. Ovariectomy
  • [MeSH-minor] Animals. Base Sequence. Biomechanical Phenomena. Body Weight / drug effects. Carrier Proteins / genetics. Cell Line. DNA Primers. Female. Glycoproteins / genetics. Membrane Glycoproteins / genetics. Osteoprotegerin. RANK Ligand. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Tumor Necrosis Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Uterus / drug effects

  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204939.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA Primers; 0 / Glycoproteins; 0 / Membrane Glycoproteins; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / Tnfrsf11b protein, rat
  •  go-up   go-down


Advertisement
4. Inoue M: [Prognostic factors uterine corpus cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2008-13
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors uterine corpus cancer].
  • FIGO staging has taken into consideration of the tumor expansion and is the most important predictor in evaluating patient outcome.
  • Characteristics of tumor biology, such as morphology of tumor and depth of invasion are also important prognostic considerations.
  • Molecular markers indicating genetic/molecular events in cancer biology appear to be the 3rd predictors in estimating the prognosis.
  • Finally, treatment of uterine corpus cancer can be directly related to prognosis.
  • Postoperative chemotherapy is gradually taking precedence over irradiation in considering evidence-based medicine.
  • [MeSH-major] Lymph Nodes / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197744.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


5. Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, Okada H, Maeda M, Ouchi Y: FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun; 2006 Jun;27(6):481-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer.
  • OBJECTIVE: For surgical planning of uterine corpus cancer, prior knowledge of the depth of myometrial invasion is important.
  • Curative tumour resection is possible in superficial invasion (stages IA and IB), while post-surgical chemotherapy or radiation therapy is required in deep invasion (stage IC).
  • We evaluated the value of positron emission tomography with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG PET) for estimating the myometrial invasion in uterine corpus cancer.
  • METHODS: We studied 22 patients with clinical stage I uterine corpus cancer, who underwent FDG PET prior to surgery.
  • Standardized uptake value (SUV; tracer activity per injected dose normalized to body weight) was calculated on the PET image.
  • FDG PET may be feasible for predicting the myometrial infiltration of uterine corpus cancer, especially when uterine atrophy makes it difficult at MRI in post-menopausal patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Myometrium / pathology. Myometrium / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Uterine Neoplasms / pathology. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Preoperative Care / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710101.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group: Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat; 2008 Nov;112(1):99-108
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
  • Tamoxifen increases the risk of uterine corpus cancer.
  • Since only few, mostly small, studies have examined prognosis of uterine corpus cancer following tamoxifen, we conducted a large retrospective cohort study to further investigate this.
  • We examined histopathologic and immunohistochemical characteristics of 332 patients with uterine corpus cancer following breast cancer, according to tamoxifen use.
  • Uterine corpus cancers in long-term tamoxifen users were more often steroid receptor-negative (ERalpha, PRA and PRB, P<0.05) and P53-positive (P=0.015).
  • Three-year uterine corpus cancer-specific survival was worse for long-term tamoxifen users than for non-users (82% vs. 93% P=0.0001).
  • The survival difference remained after adjustment for histopathologic and immunohistochemical characteristics (hazard ratio (HR) for >or=2 years tamoxifen=2.4; 95% CI=1.2-4.6).
  • Our results can be applied when weighing risks and benefits of tamoxifen versus other hormonal agents used in the prevention and treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Aged. Cohort Studies. Cystadenocarcinoma, Serous / chemically induced. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / mortality. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / mortality. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / diagnosis. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / diagnosis. Sarcoma / mortality. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064567.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Visser O; Damhuis RA; Louwman WJ; van Dijck JA; Westerman Y; Dirx MJ; Jansen-Landheer ML; de Munck L; Siesling S
  •  go-up   go-down


7. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ; 2007 Sep 29;335(7621):651
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study.
  • OBJECTIVE: To examine the absolute risks or benefits on cancer associated with oral contraception, using incident data.
  • MAIN OUTCOME MEASURES: Adjusted relative risks between never and ever users of oral contraceptives for different types of cancer, main gynaecological cancers combined, and any cancer.
  • Standardisation variables were age, smoking, parity, social class, and (for the general practitioner observation dataset) hormone replacement therapy.
  • Subgroup analyses examined whether the relative risks changed with user characteristics, duration of oral contraception usage, and time since last use of oral contraception.
  • Compared with never users ever users had statistically significant lower rates of cancers of the large bowel or rectum, uterine body, and ovaries, tumours of unknown site, and other malignancies; main gynaecological cancers combined; and any cancer.
  • The relative risk for any cancer in the smaller general practitioner observation dataset was not significantly reduced.
  • Statistically significant trends of increasing risk of cervical and central nervous system or pituitary cancer, and decreasing risk of uterine body and ovarian malignancies, were seen with increasing duration of oral contraceptive use.
  • Reduced relative risk estimates were observed for ovarian and uterine body cancer many years after stopping oral contraception, although some were not statistically significant.
  • The estimated absolute rate reduction of any cancer among ever users was 45 or 10 per 100,000 woman years, depending on whether the main or general practitioner observation dataset was used.
  • CONCLUSION: In this UK cohort, oral contraception was not associated with an overall increased risk of cancer; indeed it may even produce a net public health gain.
  • The balance of cancer risks and benefits, however, may vary internationally, depending on patterns of oral contraception usage and the incidence of different cancers.

  • Genetic Alliance. consumer health - Oral cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):722-7 [11237397.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):385-9 [16819539.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):552-3 [16094770.001]
  • [Cites] BMJ. 2005 Jun 25;330(7506):1482 [15930026.001]
  • [Cites] J Epidemiol Community Health. 2001 Jun;55(6):414-22 [11351000.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):370-4 [11668519.001]
  • [Cites] Drug Saf. 2001;24(10):741-54 [11676302.001]
  • [Cites] Lancet. 2003 Apr 5;361(9364):1159-67 [12686037.001]
  • [Cites] Tidsskr Nor Laegeforen. 2003 Jun 12;123(12):1653-6 [12821980.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1331-5 [2904052.001]
  • [Cites] Ann Intern Med. 1994 May 15;120(10):821-6 [8154642.001]
  • [Cites] Lancet. 1996 Jun 22;347(9017):1713-27 [8656904.001]
  • [Cites] J Epidemiol Community Health. 1998 Jul;52(7):420-4 [9799875.001]
  • [Cites] BMJ. 1999 Jan 9;318(7176):96-100 [9880284.001]
  • [Cites] Cancer Causes Control. 1999 Aug;10(4):277-84 [10482486.001]
  • [CommentIn] BMJ. 2007 Sep 29;335(7621):621-2 [17855281.001]
  • [CommentIn] Natl Med J India. 2008 Sep-Oct;21(5):234-5 [19320323.001]
  • [CommentIn] BMJ. 2008 Jan 12;336(7635):59-60; author reply 60 [18187700.001]
  • [CommentIn] J Fam Pract. 2008 Feb;57(2):83 [18254189.001]
  • (PMID = 17855280.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  • [Other-IDs] NLM/ PMC1995533
  •  go-up   go-down


8. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science; 2002 Oct 25;298(5594):843-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classical genotropic actions of sex steroid receptors are dispensable for their bone protective effects, but essential for their effects on reproductive tissues.
  • Such ligands merit investigation as potential therapeutic alternatives to hormone replacement for osteoporosis in both women and men [corrected].
  • [MeSH-major] Bone Density / drug effects. Bone and Bones / drug effects. Estrenes / pharmacology. Osteoblasts / drug effects. Osteoclasts / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Body Weight / drug effects. Breast Neoplasms / pathology. Cell Division / drug effects. Cells, Cultured. Compressive Strength / drug effects. Dihydrotestosterone / pharmacology. Estradiol / pharmacology. Female. Humans. Male. Mice. Orchiectomy. Organ Size / drug effects. Osteocalcin / blood. Osteogenesis / drug effects. Osteoporosis / drug therapy. Ovariectomy. Pyrazoles / pharmacology. Receptors, Estrogen / metabolism. Seminal Vesicles / drug effects. Transcription, Genetic / drug effects. Tumor Cells, Cultured. Uterus / drug effects. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Bone Density.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Science. 2002 Oct 25;298(5594):723-4 [12399556.001]
  • [ErratumIn] Science. 2003 Feb 21;299(5610):1184
  • (PMID = 12399595.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO2-AR02127; United States / NIA NIH HHS / AG / P01-AG13918
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-estren-3,17-diol; 0 / Estrenes; 0 / Pyrazoles; 0 / Receptors, Estrogen; 08J2K08A3Y / Dihydrotestosterone; 104982-03-8 / Osteocalcin; 3QD5KJZ7ZJ / pyrazole; 4TI98Z838E / Estradiol
  •  go-up   go-down


9. Tanase Y, Kawaguchi R, Haruta S, Kanayama S, Yamada Y, Kobayashi H: [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide]. Gan To Kagaku Ryoho; 2006 Jul;33(7):945-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
  • The therapeutic efficacy and adverse reactions were compared between 14 patients who received TJ therapy using paclitaxel (PTX) and carboplatin (CBDCA) and 39 who received CAP therapy using cyclophosphamide (CPA), doxorubicin (DXR) and cisplatin (CDDP) as postoperative chemotherapy for cancer of the uterine body.
  • In TJ therapy, PTX (175 mg/m(2)) and CBDCA (AUC 5) were administered on Day 1 (every 3 weeks), while in CAP therapy, CPA (500 mg/m(2)), DXR (40 mg/m(2)) and CDDP (50 mg/m(2)) were administered on Day 1 (every 4 weeks).
  • Grade 3 or severe non-hematologic toxicities included nausea (0%, 15.4%) and vomiting (0%, 12.8%) with significantly higher incidence in the CAP therapy group (p=0.0000736, p=0.000736), peripheral sensory disturbance (7.1%, 0%) and arthralgia (7.1%, 0%) with significantly higher incidence in the TJ therapy group (p=0.00129, p=0.00000538).
  • TJ therapy is thought to be as effective as CAP therapy, and can be safely conducted, although precautions are required regarding arthralgia and neuropathy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterectomy. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835485.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr: Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst; 2004 Jan 7;96(1):70-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.
  • Recent studies have indicated that the tamoxifen-related risk of uterine corpus cancer may be especially high for some uncommon cell types, although the magnitude of risk has not been quantified.
  • We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2.17, 95% confidence interval [CI] = 1.95 to 2.41) relative to the general SEER population.
  • The relative risk was substantially higher for malignant mixed mullerian tumors (MMMTs) (O/E = 4.62, O = 34, 95% CI = 3.20 to 6.46) than for endometrial adenocarcinomas (O/E = 2.07, O = 306, 95% CI = 1.85 to 2.32), although the excess absolute risk was smaller-an additional 1.4 versus 8.4 cancers per 10 000 women per year, respectively.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Estrogen Receptor Modulators / adverse effects. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adult. Aged. Carcinoma, Ductal / drug therapy. Confidence Intervals. Female. Humans. Middle Aged. Odds Ratio. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14709741.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


11. Teplitzky SR, Kiefer TL, Cheng Q, Dwivedi PD, Moroz K, Myers L, Anderson MB, Collins A, Dai J, Yuan L, Spriggs LL, Blask DE, Hill SM: Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett; 2001 Jul 26;168(2):155-63
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.
  • In experimental trials using the N-nitroso-N-methylurea (NMU)-induced rat mammary tumor model, a significant decrease in tumor incidence (to 5%) was observed in rats treated with melatonin and 9-cis-retinoic acid (9 cRA) compared to controls (55%).
  • Although 9cRA alone decreased tumor incidence to 26%, this response did not reach statistical significance.
  • Tumor incidence was significantly inhibited to 20% in the animals that received melatonin and 9cRA on alternating days.
  • Latency to tumor onset was prolonged in animals receiving either of the combination treatments compared with controls, and tumor multiplicity was also significantly decreased.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Body Weight / drug effects. Carcinogens / antagonists & inhibitors. Drug Synergism. Drug Therapy, Combination. Estradiol / blood. Estrogen Receptor alpha. Female. Free Radical Scavengers / pharmacology. Methylnitrosourea. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Receptors, Estrogen / biosynthesis. Receptors, Retinoic Acid / biosynthesis. Uterus / anatomy & histology. Uterus / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11403920.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01CA54152-07; United States / NCI NIH HHS / CA / R01CA76197; United States / NCI NIH HHS / CA / T32CAC5436-01A3
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Free Radical Scavengers; 0 / Receptors, Estrogen; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 4TI98Z838E / Estradiol; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; 684-93-5 / Methylnitrosourea; JL5DK93RCL / Melatonin
  •  go-up   go-down


12. Sairam MR, Danilovich N, Lussier-Cacan S: The FORKO mouse as a genetic model for exploring estrogen replacement therapy. J Reprod Med; 2002 May;47(5):412-8
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The FORKO mouse as a genetic model for exploring estrogen replacement therapy.
  • OBJECTIVE: To evaluate how chronically estrogen deficient female FORKO mice with genetic disruption of the FSH receptor respond to estrogen therapy.
  • STUDY DESIGN: Subcutaneous estrogen agonist or antagonist therapy was initiated to study reproductive tissue response, adipose tissue mass and plasma lipid profiles.
  • RESULTS: Within 36-48 hours of agonist administration, the classic measures of estrogenic activity were evident in the uterus and vagina.
  • Older animals also responded to therapy during a 10-day period, indicating that estrogen receptor signaling systems are unaffected by aging.
  • In these obese mutants, this short treatment decreased adipose tissue in all areas and corrected lipid abnormalities.
  • Tamoxifen, a nonsteroidal mixed estrogen agonist and antagonist, had marginal effects on the uterus and body fat of FORKO mice, indicating differences in interaction.
  • Hence, this is a useful model for studying estrogen replacement therapy and helps resolve questions related to efficacy and actions.
  • [MeSH-major] Disease Models, Animal. Estradiol / pharmacology. Estrogen Antagonists / pharmacology. Estrogen Replacement Therapy. Tamoxifen / pharmacology
  • [MeSH-minor] Adipose Tissue / drug effects. Animals. Apolipoproteins E / blood. Cholesterol / blood. Cholesterol, HDL / blood. Female. Mice. Mice, Knockout. Models, Genetic. Receptors, FSH / deficiency. Receptors, FSH / genetics. Testosterone / blood. Triglycerides / blood. Uterus / drug effects. Vagina / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063881.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Cholesterol, HDL; 0 / Estrogen Antagonists; 0 / Receptors, FSH; 0 / Triglycerides; 094ZI81Y45 / Tamoxifen; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


13. Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst; 2001 Oct 3;93(19):1449-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
  • SERMs also have different degrees of estrogenicity in the uterus.
  • Tamoxifen is used specifically to reduce the incidence of breast cancer in premenopausal and postmenopausal women at risk for the disease.
  • The study of tamoxifen and raloxifene (STAR) trial is currently comparing the ability of these SERMs to reduce breast cancer incidence in high-risk postmenopausal women.
  • There is intense interest in understanding the molecular mechanism(s) of action of SERMs at target sites in a woman's body.
  • An understanding of the targeted actions of this novel drug group will potentially result in the introduction of new multifunctional medicines with applications as preventive agents or treatments of breast cancer and endometrial cancer, coronary heart disease, and osteoporosis.
  • [MeSH-major] Breast Neoplasms / prevention & control. Coronary Disease / prevention & control. Osteoporosis / prevention & control. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Adult. Aged. Bone and Bones / drug effects. Breast / drug effects. Cardiovascular System / drug effects. Cinnamates / pharmacology. Clinical Trials as Topic. Endometrial Neoplasms / chemically induced. Estrogen Replacement Therapy. Female. Heart / drug effects. Hot Flashes / chemically induced. Humans. Middle Aged. Models, Biological. Organ Specificity. Postmenopause. Premenopause. Prospective Studies. Protein Structure, Tertiary / drug effects. Raloxifene Hydrochloride / adverse effects. Raloxifene Hydrochloride / pharmacology. Raloxifene Hydrochloride / therapeutic use. Randomized Controlled Trials as Topic. Receptors, Estrogen / analysis. Receptors, Estrogen / drug effects. Risk. Risk Assessment. Stilbenes / pharmacology. Tamoxifen / adverse effects. Tamoxifen / pharmacology. Tamoxifen / therapeutic use. Thrombophilia / chemically induced. Transcription, Genetic / drug effects

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Osteoporosis.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. RALOXIFENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584060.001).
  • [ISSN] 0027-8874
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89018-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cinnamates; 0 / GW 7604; 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators; 0 / Stilbenes; 094ZI81Y45 / Tamoxifen; 4F86W47BR6 / Raloxifene Hydrochloride
  • [Number-of-references] 96
  •  go-up   go-down


14. Tsai MH, Huang GS, Hung YC, Bin L, Liao LT, Lin LW: Psoralea corylifolia extract ameliorates experimental osteoporosis in ovariectomized rats. Am J Chin Med; 2007;35(4):669-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCL extract (25 mg or 50 mg/kg body weight/day) was orally administrated to OVX rats for 3 months.
  • PCL extract did not alter weight gain or uterus weight in OVX rats.
  • PCL extract significantly increased serum Ca (calcium) levels (p < 0.05, vs.
  • OVX group) as well as decreased urinary Ca excretion (p < 0.05 vs. OVX group) in OVX rats.
  • The upregulation of serum osteocalcin level by ovariectomy was suppressed by treatment with PCL extract in rats (p < 0.05, vs. OVX group).
  • PCL extract increased bone mineral density at 50 mg/kg body weight/day in OVX rats (p < 0.05, vs. OVX group).
  • In conclusion, our studies showed that PCL might be a potential candidate for treatment of postmenopausal osteoporosis.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Osteoporosis / etiology. Osteoporosis / prevention & control. Ovariectomy / adverse effects. Psoralea
  • [MeSH-minor] Administration, Oral. Animals. Bone Density / drug effects. Bone Density / physiology. Bone Resorption / drug therapy. Bone and Bones / metabolism. Bone and Bones / pathology. Calcium / metabolism. Disease Models, Animal. Female. Osteocalcin / blood. Osteogenesis / drug effects. Phytotherapy / methods. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708633.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 104982-03-8 / Osteocalcin; SY7Q814VUP / Calcium
  •  go-up   go-down


15. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol; 2005 Apr;192(4):1230-7; discussion 1237-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
  • OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project.
  • Comparisons included stratification by menopausal status, body mass index, and history of estrogen use.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology. Neoplasm Recurrence, Local / prevention & control. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Probability. Reference Values. Risk Assessment

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205 [16580343.001]
  • (PMID = 15846210.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


16. Thawornkaiwong A, Preawnim S, Wattanapermpool J: Upregulation of beta 1-adrenergic receptors in ovariectomized rat hearts. Life Sci; 2003 Mar 7;72(16):1813-24
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in cardiac myofilament Ca(2+) activation have been demonstrated in ovariectomized rats.
  • Subcutaneous injection of estrogen (5 microg/rat), progesterone (1 mg/rat), or estrogen plus progesterone three times a week all effectively prevented the upregulation of the beta(1)-adrenoceptors.
  • [MeSH-minor] Adrenergic beta-1 Receptor Antagonists. Animals. Body Weight / drug effects. Drug Therapy, Combination. Estrogens / administration & dosage. Estrogens / pharmacology. Female. Heart / drug effects. Immunoblotting. Injections, Subcutaneous. Organ Size / drug effects. Progesterone / administration & dosage. Progesterone / pharmacology. Rats. Rats, Sprague-Dawley. Sarcolemma / metabolism. Up-Regulation. Uterus / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12586219.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-1 Receptor Antagonists; 0 / Estrogens; 0 / Receptors, Adrenergic, beta-1; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


17. Bennett JA, DeFreest L, Anaka I, Saadati H, Balulad S, Jacobson HI, Andersen TT: AFPep: an anti-breast cancer peptide that is orally active. Breast Cancer Res Treat; 2006 Jul;98(2):133-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AFPep: an anti-breast cancer peptide that is orally active.
  • BACKGROUND: We have synthesized a cyclic nonapeptide (AFPep) that is effective, after being administered by parenteral routes, for the treatment or the prevention of breast cancer.
  • METHODS: Using a human breast cancer xenograft model in mice for therapeutic activity, a carcinogen-induced breast cancer model in rats for prevention efficacy, and a mouse uterus growth inhibition model of anti-estrogenic activity, AFPep was administered by oral gavage (p.o.) and its effects compared to those following intraperitoneal (i.p.) and subcutaneous (s.c.) administration.
  • Toxicity studies evaluated body weights and organ weights in mice and rats receiving AFPep.
  • Preliminary mechanistic studies were carried out in T47D human breast cancer cells growing in culture and evaluated the effect of AFPep on estrogen-stimulated cell growth, phosphorylation of the estrogen receptor (ER), and on level of ER-related kinases.
  • RESULTS: Orally administered AFPep stopped the growth of human tumor xenografts in mice, decreased the incidence and multiplicity of breast cancers in carcinogen-exposed rats, and inhibited the estrogen-stimulated growth of mouse uteri.
  • CONCLUSIONS: Chronic oral administration of AFPep appears to be safe and effective for the treatment or prevention of breast cancer in animal models.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Peptides, Cyclic / therapeutic use. alpha-Fetoproteins
  • [MeSH-minor] Administration, Oral. Animals. Cell Line, Tumor. Humans. Male. Mice. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538538.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Vilos GA, Tureanu V, Garcia M, Abu-Rafea B: The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy. J Minim Invasive Gynecol; 2009 Jul-Aug;16(4):480-4
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.
  • OBJECTIVE: To evaluate the efficacy of levonorgestrel intrauterine systems (LNG-IUS) in obese women with AUB on anticoagulant therapy.
  • PATIENTS: Premenopausal women on Warfarin therapy.
  • MEASUREMENTS AND MAIN RESULTS: The median and range of age, parity, and body mass index were 45 years (34-49), 1 (0-4), and 38 kg/m(2) (26-52), respectively.
  • All women were receiving warfarin therapy (4-12.5 mg/d) for previous venous thromboembolism.
  • Some patients had additional comorbid conditions and were at high risk for traditional medical or surgical therapies.
  • By 12 months, 1 woman with large fibroids expelled the LNG-IUS and was treated with transfemoral uterine artery embolization.
  • At 2 to 5 years, 1 woman expelled the LNG-IUS and hysterectomy indicated extensive adenomyosis in a 195-g uterus, and 1 woman had hysteroscopic endometrial ablation, 4 were menopausal, 2 had amenorrhea, and 1 had hypomenorrhea.
  • In the 5 women with uterine fibroids measuring 4.2 to 147 cm(3), the fibroids were reduced in volume by approximately 75% in 2, were no longer detectable in 1, were subsequently shown to be adenomyoma in 1, and required uterine artery embolization in 1.
  • CONCLUSION: In properly assessed and selected obese, premenopausal women with AUB receiving warfarin therapy and at high risk for traditional therapies, the LNG-IUS was an effective treatment in 70% of patients.
  • [MeSH-major] Contraceptives, Oral, Synthetic / therapeutic use. Intrauterine Devices, Medicated. Levonorgestrel / therapeutic use. Metrorrhagia / complications. Metrorrhagia / drug therapy. Thrombosis / complications
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Female. Humans. Middle Aged. Obesity / complications. Prospective Studies. Warfarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573825.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Contraceptives, Oral, Synthetic; 5Q7ZVV76EI / Warfarin; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


19. Zhu H, Jiang YJ, Liang L: [Long-acting gonadotropin-releasing hormone analogue in treatment of idiopathic central precocious puberty in girls]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 May;37(3):295-9
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-acting gonadotropin-releasing hormone analogue in treatment of idiopathic central precocious puberty in girls].
  • OBJECTIVE: To investigate the efficacy and side-effects of long-acting gonadotropin-releasing hormone analogue (GnRHa) in treatment of idiopathic central precocious puberty (ICPP) in girls.
  • The secondary sexual characteristics, uterus volume, ovary volume, follicle development, bone age/chronological age (BA/CA), predicted adult height (PAH), serum inhibitor A (INHA) and inhibitor B (INHB), body mass index (BMI) and growth rate were compared before and after treatment.
  • (1) Breast development was reduced after 3 to approximately 6 months of treatment, and no continued development were observed.
  • In 12 girls the breast development returned from Tanner II to B1. (2) Both uterus and ovary volume were decreased after 6 months [(3.28 +/-2.20)ml comrade with (1.27 +/-0.69)ml and (3.62 +/-1.94)ml compared with (1.24 +/-0.50)ml, respectively]; the follicle was reduced or even disappeared; and the serum INHA and INHB were decreased from Log(0.93 +/-0.35)ng/L and Log(1.95 +/-0.37)ng/L to Log(0.60 +/-0.32)ng/L and Log(1.46 +/-0.32)ng/L, respectively. (3) BA/CA was decreased from 1.40 +/-0.20 to 1.26 +/-0.15; PAH was increased from (149.12 +/-4.04)cm to (152.84 +/-3.72)cm after one-year treatment; BMI showed no significant changes (16.04 +/-1.68 compared with 15.93 +/-1.69).
  • CONCLUSION: GnRHa can effectively inhibit the development of sex gland and the secondary sexual characteristics, stabilize or delay bone maturation, improve the predicted adult height, and has no observed side-effects in the short-term treatment for ICPP girls.
  • [MeSH-major] Gonadotropin-Releasing Hormone / administration & dosage. Gonadotropin-Releasing Hormone / analogs & derivatives. Puberty, Precocious / drug therapy
  • [MeSH-minor] Child. Delayed-Action Preparations / therapeutic use. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546534.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


20. Hara K, Tada M, Naruse S, Soma Y, Kojima Y, Kurata H, Tanaka K, Tsuji S: [Two cases of lumbosacral radiculopathy after intra-arterial infusion of cisplatin for treatment of uterine cancer]. Rinsho Shinkeigaku; 2003 Jan-Feb;43(1-2):26-30
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of lumbosacral radiculopathy after intra-arterial infusion of cisplatin for treatment of uterine cancer].
  • A 60-year-old woman (case 1) experienced severe pain in the lower part of her leg and sciatic nerve paralysis the following day after intra-arterial infusion of cisplatin for the treatment of uterine body cancer.
  • A 49-year-old woman (case 2) complained of severe pain in the lower part of her leg three days after intra-arterial infusion of cisplatin for the treatment of uterocervical cancer.
  • The symptoms gradually improved with the symptomatic therapy.
  • It was suggested that lumbo-sacral radiculopathy induced by intra-arterial infusion of cisplatin is not a rare complication and that MRI is useful in confirming the diagnosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. Radiculopathy / chemically induced. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infusions, Intra-Arterial. Lumbosacral Region. Magnetic Resonance Imaging. Middle Aged. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820547.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshò„ shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down






Advertisement